Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033199 | 0.93 | CYP11B1 (0.33) | CYP11B1CYP11B2CETP | |
| SCHEMBL14926786 | 0.88 | GRM2 (0.36) | GRM2ALOX5APFEN1CETP | |
| SCHEMBL19478660 | 0.87 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL14888020 | 0.85 | GRM2 (0.35) | GRM2ALOX5APFEN1CETP | |
| SCHEMBL18820206 | 0.85 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL17177805 | 0.85 | GRM2 (0.36) | GRM2ALOX5APFEN1CETP | |
| SCHEMBL20310614 | 0.85 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL12624481 | 0.84 | ALOX5AP (0.34) | GRM2ALOX5APFEN1 | |
| SCHEMBL21475544 | 0.83 | GRM2 (0.34) | GRM2ALOX5APFEN1CETP | |
| SCHEMBL14888021 | 0.83 | GRM2 (0.34) | GRM2ALOX5APFEN1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738831-B2 | Optically isotropic liquid crystal composition and optical device | JNC CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9738831-B2 | Optically isotropic liquid crystal composition and optical device | JNC CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20150240159-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL COMPOSITION AND OPTICAL DEVICE | JNC CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150240159-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL COMPOSITION AND OPTICAL DEVICE | JNC CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240159-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL COMPOSITION AND OPTICAL DEVICE | SCO2, CNOT1, LEO1 | GRM2 1980/4885CYP11B1 1012/4885CYP11B2 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.